We talk with Benjamin Lightburn, CEO and cofounder of Filament Health, about blending natural psychedelics with novel technology. We discuss the "entourage effect," Vancouver dispensaries openly selling psychedelics, and Filament's mystery psychedelic compound in development.
Video
Audio
Highlights
— THE NUGGET: Toronto and Michigan with new psychedelic legalization bills (0:32)
— THE NOODLE: How to compare MDMA, LSD & psilocybin indications (0:53)
— Why Filament chose natural psilocybin and their approach to IP (1:28)
— Does the "entourage effect" work, and how to prove it (6:49)
— Psychedelic "suggestion bias" (8:12)
— The path for healthy people to pursue legal psychedelics (11:30)
— The case for legalization (13:23)
— Dispensaries in Vancouver are openly selling magic mushrooms (16:24)
— The first pharmaceutical grade natural psychedelic product (17:55)
— SOUL SEARCH: Ben's preferred mind-altering substance on a desert island (21:20)
— SLAP and a CLAP: Eleusis and Novamind (24:53)
Ben Lightburn
He is a proven entrepreneur and leader specializing in the research, development and commercialization of novel extraction technologies.
He is applying this experience to the delivery of psychedelic medicines as CEO and Co-Founder of Filament Health
Find Ben here:
See the inspiration behind the Psychedelic Diaries here.
Comments